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ABSTRACT 
This study investigated the effects of size, size distribution, specific surface area, 
surface roughness, crystallinity, and fine content (< 5 pim fraction) of lactose 
microcarrier on the pulmonary inhalation profiles of rifampicin encapsulated in 
polyvinylpyrrolidone nanoparticles (194.77 ± 9.52 ran). The spherical lactose was 
modified through solvation and reprecipitation processes using aqueous ethanolic 
solution with different ethanol contents. The reprecipitated lactose had smaller 
particle size, wider size distribution, larger specific surface area, more elongated 
shape, smoother surface texture and lower crystallinity than the unprocessed lactose. 
They contained fine particles of sizes smaller than 5 /an of which none was found in 
the unprocessed lactose. Cascade impactor and scanning electron microscopy analysis 
of lactose-nanoparticle blends indicated that unprocessed lactose carried nanoparticles 
through surface adsorption and pore immersion methods. The small, less crystalline 
and elongated processed lactose carried nanoparticles through surface adsorption and 
encapsulation via inter-lactose aggregation. The aggregative tendency of these 
lactoses increased with reduced size and crystallinity and a increased surface 
roughness that provided more active sites for particulate interaction. This improved 
the fine particle dose, fine particle fraction, percent dispersed, percent inhaled of 
nanoparticles due to their ability to remain attaching to lactose during aerosolization, 
and detach for deep lung deposition in late time domain unlike those immersed in 
pores of unprocessed lactose. Overall, a lactose fine content amounting to less than 
9 % or more than 12 % was detrimental to aerosolization. Excessive fine reduced 
nanoparticle attachment. Suboptimal fine content discouraged nanoparticle 
detachment and deposition. 
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CHAPTER ONE 
INTRODUCTION 
1.1 BACKGROUND OF STUDY 
1.1.1 Pulmonary Drug Delivery 
Pulmonary drug delivery has received considerable attention from researchers 
as an effective and convenient alternative route of drug administration to the 
conventional oral and injection modes. Pulmonary delivery enables to target drug 
directly to lung for both local and systemic treatment [1, 2]. Local delivery of 
medication to the lungs is highly desirable, especially in cystic fibrosis, asthma, 
chronic pulmonary infections or lung cancer patients. It offers several advantages 
including delivery of high drug concentrations directly to the target region, rapid 
clinical response, improving efficacy and reducing systemic side effect. Pulmonary 
delivery is also an attractive option systemic treatment because the respiratory region 
mainly alveoli provides an enormous surface area (80 to 100m2 /adult) and highly 
permeable membrane for the absorption of medication into the blood to achieve 
maximum systemic uptake to the target region. It is a non-invasive ‘needle-free’ 
delivery system and suitable for wide range of substances from small molecules to 
very large proteins. Large protein molecules which degrade in the harsh 
gastrointestinal conditions and are eliminated by first-pass metabolism in the liver can 
be delivered via pulmonary route if deposited in the respiratory zone of the lungs [1], 
The fate of delivered medication depends on the mechanism and rate of 
elimination in the respiratory tract. Upon therapeutic agent depositing in the lung, its 
elimination is immediately initiated thereby reducing the initially high local drug 
concentration in lung tissue [3-5], Generally, multiple daily inhalations up to 9 times 
are required to compensate for the rapid decay of drug concentrations [6]. Apart from 
the pulmonary morphological aspects and ventilatory parameters, drug formulation 
and the design of potential carrier system with specific physicochemical properties 
such as size, shape, surface chemistry, and bioadhesive properties are very crucial to 
bypass the clearance mechanisms of the lung thereby providing prolonged residence 
times to therapeutic agent within the respiratory tract [7], Alternative strategies 
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